To see what people are saying about these Merck® Drugs please view our Fourm.
Common Misspellings:
(Losartan Potassium)
Cozaar® is in a class of drugs called angiotensin II receptor antagonists, along with Hyzaar®. The prescription medicine Cozaar® is indicated for the treatment of hypertension, or high blood pressure. Cozaar® can reduce the risk of stroke for patients who suffer from hypertension and left ventricular hypertrophy. Evidence suggests that the medicine Cozaar® does not work with Black patients.
Losartan Potassium is the generic name for the prescription medicine Cozaar ®.
If you experience any of the following side effects while taking the prescription medicine Cozaar®, discontinue use immediately and contact your doctor: an allergic reaction or difficulty urinating.
Some more common side effects you might experience while taking the prescription medicine Cozaar® are: diarrhea or upset stomach, muscle pain or cramps, dizziness, or insomnia.
Side effects are difficult to predict. Some side effects are normal, while other side effects are not. Some side effects are not listed here, so as always, discuss any side effects you are experiencing while taking any prescription medicine, including Cozaar®, with your doctor.
Cozaar and Hyzaar: Leaders in Their Class 2001 was another strong year for Cozaar/Hyzaar . Together, these medicines are the global leader in the angiotensin II antagonist (AIIA) class of antihypertensive drugs, with 2001 sales of $1.9 billion; they already rank No. 2 among all branded medicines prescribed for the treatment of high blood pressure. This bodes well for the future, given that AIIAs provide most of the impetus for growth in the global antihypertension market. Physicians have prescribed Cozaar and Hyzaar for 12 million patients since their launch in 1995.
This performance featured the 47 percent growth of Cozaar/Hyzaar in the important Japanese market (where it is known as Nu-lotan ); a sustained marketing success in Europe ; and strong growth in the United States , despite a tough competitive market. All this helped increase sales by 11 percent over 2000.
During 2001, we maintained a focus on communicating the proven once-daily blood pressure lowering efficacy as well as tolerability of Cozaar and Hyzaar .
RENAAL may open new markets
Our clinical scientists also completed two key studies this year: one focusing on the use of Cozaar in treating high blood pressure in children and a second, called RENAAL, in which Cozaar delayed the progression of kidney disease in patients with Type 2 diabetes and kidney disease. We have submitted the results of both studies to regulatory agencies worldwide, including the U.S. Food and Drug Administration, for potential inclusion in the prescribing information for Cozaar .
Some 185 million people in the developed world suffer from hypertension. By 2008, that number will be 200 million. At present, only 55 percent of these people are being treated with any medicine and, of those being treated, many have not reached appropriate blood pressure goals.
Additional important outcomes studies with Cozaar and Hyzaar are ongoing. In 2002, results are expected from large studies examining the potential survival benefits for patients taking Cozaar who suffer from hypertension with associated end organ damage and for patients taking Cozaar following a heart attack. In addition, Merck expects results from a study in which Hyzaar is being evaluated for use in a special population of patients with severe hypertension.
Source: http://www.anrpt2001.com/1.htm